773 related articles for article (PubMed ID: 28345443)
41. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
[TBL] [Abstract][Full Text] [Related]
42. Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System.
Sussman M; O'sullivan AK; Shah A; Olfson M; Menzin J
J Manag Care Spec Pharm; 2019 Jul; 25(7):823-835. PubMed ID: 31232205
[TBL] [Abstract][Full Text] [Related]
43. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.
Burger CD; Ozbay AB; Lazarus HM; Riehle E; Montejano LB; Lenhart G; White RJ
J Manag Care Spec Pharm; 2018 Aug; 24(8):834-842. PubMed ID: 29436260
[TBL] [Abstract][Full Text] [Related]
44. Comparative Assessment of Medical Resource Use and Costs Associated with Patients with Symptomatic Peripheral Artery Disease in the United States.
Chase MR; Friedman HS; Navaratnam P; Heithoff K; Simpson RJ
J Manag Care Spec Pharm; 2016 Jun; 22(6):667-75. PubMed ID: 27231794
[TBL] [Abstract][Full Text] [Related]
45. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
[TBL] [Abstract][Full Text] [Related]
46. Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data.
Burudpakdee C; Lin HM; Wang W; Seetasith A; Zhu Y; Bonthapally V; Carson KR
J Med Econ; 2016 Oct; 19(10):965-72. PubMed ID: 27152635
[TBL] [Abstract][Full Text] [Related]
47. Direct Costs of Opioid Abuse in an Insured Population in the United States.
White AG; Birnbaum HG; Mareva MN; Daher M; Vallow S; Schein J; Katz N
J Manag Care Spec Pharm; 2020 Oct; 26(10):1188-1198. PubMed ID: 32996392
[TBL] [Abstract][Full Text] [Related]
48. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation.
Nellesen D; Yee K; Chawla A; Lewis BE; Carson RT
J Manag Care Pharm; 2013; 19(9):755-64. PubMed ID: 24156644
[TBL] [Abstract][Full Text] [Related]
49. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
[TBL] [Abstract][Full Text] [Related]
50. Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States.
Bell CF; Blauer-Peterson C; Mao J
J Manag Care Spec Pharm; 2021 Sep; 27(9):1249-1259. PubMed ID: 34165321
[No Abstract] [Full Text] [Related]
51. Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US.
Pike C; Birnbaum HG; Schiller M; Sharma H; Burge R; Edgell ET
Pharmacoeconomics; 2010; 28(5):395-409. PubMed ID: 20402541
[TBL] [Abstract][Full Text] [Related]
52. Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis.
Croteau SE; Cook K; Sheikh L; Chawla A; Sammon J; Solari P; Kim B; Hinds D; Thornburg CD
J Manag Care Spec Pharm; 2021 Mar; 27(3):316-326. PubMed ID: 33645244
[No Abstract] [Full Text] [Related]
53. Annual Costs of Care for Pediatric Irritable Bowel Syndrome, Functional Abdominal Pain, and Functional Abdominal Pain Syndrome.
Hoekman DR; Rutten JM; Vlieger AM; Benninga MA; Dijkgraaf MG
J Pediatr; 2015 Nov; 167(5):1103-8.e2. PubMed ID: 26329806
[TBL] [Abstract][Full Text] [Related]
54. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
[No Abstract] [Full Text] [Related]
55. Variation in Care for Patients with Irritable Bowel Syndrome in the United States.
Lacy BE; Patel H; Guérin A; Dea K; Scopel JL; Alaghband R; Wu EQ; Mody R
PLoS One; 2016; 11(4):e0154258. PubMed ID: 27116612
[TBL] [Abstract][Full Text] [Related]
56. The direct and indirect costs among U.S. privately insured employees with hypogonadism.
Kaltenboeck A; Foster S; Ivanova J; Diener M; Bergman R; Birnbaum H; Kinchen K; Swindle R
J Sex Med; 2012 Sep; 9(9):2438-47. PubMed ID: 22738380
[TBL] [Abstract][Full Text] [Related]
57. Healthcare resource utilization and cost among patients with type 1 diabetes in the United States.
Simeone JC; Shah S; Ganz ML; Sullivan S; Koralova A; LeGrand J; Bushman J
J Manag Care Spec Pharm; 2020 Nov; 26(11):1399-1410. PubMed ID: 33119443
[No Abstract] [Full Text] [Related]
58. Costs and health resource use in patients with X-linked myotubular myopathy: insights from US commercial claims.
Sacks NC; Healey BE; Cyr PL; Slocomb T; James E; Beggs AH; Graham RJ
J Manag Care Spec Pharm; 2021 Aug; 27(8):1019-1026. PubMed ID: 33843254
[No Abstract] [Full Text] [Related]
59. Direct costs of opioid abuse in an insured population in the United States.
White AG; Birnbaum HG; Mareva MN; Daher M; Vallow S; Schein J; Katz N
J Manag Care Pharm; 2005; 11(6):469-79. PubMed ID: 15998164
[TBL] [Abstract][Full Text] [Related]
60. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
